PD-L1 expression as a predictive biomarker in cancer immunotherapy

Cited by (1,001)

Items 801–900 of 1,001

1. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program
   Javier Arranz‐Nicolás, Miguel Martin-Salgado, Irene Adán‐Barrientos, Rosa Liébana, María del Carmen Moreno-Ortíz, Judith Maria Leitner, Peter Steinberger, Antonia Ávila‐Flores, Isabel Mérida · 2021 · Cancer Immunology Immunotherapy
2. Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer
   Enkui Zhang, Chengsheng Ding, Shuchun Li, Batuer Aikemu, Xueliang Zhou, Xiaodong Fan, Jing Ping Sun, Xiao Yi Yang, Minhua Zheng · 2023 · Cancer Cell International
3. Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
   Robert John Motzer, Camillo Porta, Masatoshi Eto, Thomas E. Hutson, Sun Young Rha, Jaime Rafael Merchan, Eric Winquist, Howard Gurney, Viktor Grünwald, S. George et al. · 2024 · Annals of Oncology
4. Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma
   Christopher M. O Connor, Quinton L Carr, Alisa Sweazy, Kelly M. McMasters, Hongying Hao · 2025 · Cancers
5. The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures
   Ziying Lin, Yutong Xu, Yaxiong Zhang, Qihua He, Jianrong Zhang, Jianxing He, Wenhua Liang · 2016 · Oncotarget
6. Emerging Biomarkers as Predictors to Anti-Pd1/PD-L1 Therapies in Advanced Melanoma
   Kimberly Leticia Loo, ADIL I. DAUD · 2016 · Immunotherapy
7. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
   Meixuan Chen, Mariacarla Andreozzi, Barbara A. Pockaj, Michael T. Barrett, Idris Tolgay Ocal, Ann E. McCullough, Maria E. Linnaus, James Middleton Chang, Jennifer Holmes Yearley, Lakshmanan Annamalai et al. · 2017 · Modern Pathology
8. Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists
   Dana A. Emerson, William L. Redmond · 2018 · BioDrugs
9. Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma
   Xuemei Du, Ying Gao, Hongyu Zhao, Bin Li, Weimin Xue, Daye Wang · 2018 · Oncology Letters
10. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?
    Varsha M. Singh · 2020 · Current Nutrition Reports
11. KALRN mutations promote antitumor immunity and immunotherapy response in cancer
    Mengyuan Li, Yuxiang Ma, You Jia Zhong, Qian Liu, Canping Chen, Lei Qiang, Xiaosheng Wang · 2020 · Journal for ImmunoTherapy of Cancer
12. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma
    Ying Mei, Mei-Ju May Chen, Han Liang, Li Ma · 2021 · Communications Biology
13. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p
    Aichen Zhang, Kun Wang, Xiaochun Sun, Lingling Tong · 2021 · APOPTOSIS
14. Mismatch repair deficiency and clinical implications in prostate cancer
    Laura S Graham, Michael Thomas Schweizer · 2022 · The Prostate
15. Ferroptosis-Related Gene MT1G as a Novel Biomarker Correlated With Prognosis and Immune Infiltration in Colorectal Cancer
    Bi Peng, Jinwu Peng, Fanhua Kang, Wen-Qin Zhang, Emin Peng, Qingchun He · 2022 · Frontiers in Cell and Developmental Biology
16. The role of long non-coding RNA FGD5-AS1 in cancer
    Na Shun Meng He, Lin-Biao Xiang, Lei Chen, Hao‐Bin Tong, Keshen Wang, Jie Zhao, Feixue Song, Hanteng Yang, Xinyuan Wei, Zuoyi Jiao · 2022 · Bioengineered
17. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma
    Fangshi Xu, Yibing Guan, Peng Zhang, Xue Li, Yubo Ma, Mei Gao, Tie Chong, Bincheng Ren · 2022 · BMC Endocrine Disorders
18. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
    Thomas Denize, Yue Hou, Jean‐Christophe Pignon, Emily Walton, Destiny J. West, Gordon James Freeman, David A. Braun, Catherine J. Wu, Saurabh Kumar Gupta, Robert John Motzer et al. · 2022 · Clinical Cancer Research
19. A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis
    Rui Chen, Wantao Wu, Siyu Chen, Zheng-Zheng Liu, Zhipeng Wen, Jing Yu, Long-Bo Zhang, Zaoqu Liu, Jian Zhang, Peng Luo et al. · 2022 · Frontiers in Immunology
20. Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer
    Jiannan Xu, Songyao Chen, Jianming Liang, Tengfei Hao, Huabin Wang, Guangyao Liu, Xinghan Jin, Huan Li, Junchang Zhang, Changhua Zhang et al. · 2022 · Frontiers in Immunology
21. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
    Maria Pallozzi, Natalia Di Tommaso, Valeria Maccauro, Francesco Santopaolo, Antonio Gasbarrini, Francesca Romana Ponziani, Maurizio Pompili · 2022 · Cancers
22. Advanced Acral Melanoma Therapies: Current Status and Future Directions
    Yiqun Zhang, Shijie Lan, Di Wu · 2022 · Current Treatment Options in Oncology
23. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
    Matthew D. Galsky, Dean F. Bajorin, Johannes Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P. Valderrama, Marc‐Oliver Grimm et al. · 2023 · European Urology
24. PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
    Bruna Pereira Sorroche, Renan de Jesus Teixeira, Caio Augusto Pereira, Iara Viana Vidigal Santana, Lazar N. Vujanovic, Vinícius de Lima Vazquez, Lídia Maria Rebolho Batista Arantes · 2023 · Diagnostics
25. Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma
    Sanjay Prakash Bagaria, Zoran Gatalica, Todd Maney, Daniel Serie, Mansi A. Parasramka, Steven Attia, Murli Krishna, Richard Wayne Joseph · 2018 · Frontiers in Oncology
26. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients’ Profiles with Dynamic Mathematical Models
    Zvia Agur, Moran Elishmereni, Urszula Foryś, Yuri Kogan · 2020 · Clinical Pharmacology & Therapeutics
27. Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
    Hans‐Georg Wirsching, Michael Weller, Stefan Balabanov, Patrick Roth · 2021 · Cancers
28. Nivolumab in combination with ipilimumab for the treatment of melanoma
    Rajasekharan Somasundaram, Meenhard Herlyn · 2015 · Expert Review of Anticancer Therapy
29. High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
    Miguel Córdova‐Delgado, Mauricio P. Pinto, Ignacio N. Retamal, Matías Muñoz‐Medel, María Loreto Bravo, María F. Fernández, Betzabé Cisternas, Sebastián Mondaca, Cesar G Sanchez, Héctor Galindo et al. · 2019 · Cancers
30. Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer
    Shiyuan Wang, Yakun Wang, Chunlu Yu, Yiyin Cao, Yu Yao, Yi Pan, Dongqing Su, Qianzi Lu, Wuritu Yang, Yongchun Zuo et al. · 2020 · Journal of Cellular and Molecular Medicine
31. Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
    Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Antonios Papanicolau‐Sengos, Blake Burgher, Vincent Giamo, Jonathan Andreas et al. · 2020 · OncoImmunology
32. Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
    Fausto Angelo Meriggi, Alberto Zaniboni · 2020 · Cancer Immunology Immunotherapy
33. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
    Fenqi Du, Yanlong Liu · 2021 · Journal of Clinical Laboratory Analysis
34. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
    Zhenwei Zhong, Mengyao Zhang, Yanan Ning, Guanchao Mao, Xiaopei Li, Qi Deng, Xiaorui Chen, Dongliang Zuo, Xiangyu Zhao, Ermin Xie et al. · 2022 · Scientific Reports
35. Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data
    Maxim Sorokin, Marianna Zolotovskaia, Daniil M. Nikitin, Maria Suntsova, Elena V Poddubskaya, Alexander Glusker, Andrew Garazha, Alexey Moisseev, Xinmin Li, Marina I Sekacheva et al. · 2022 · BMC Cancer
36. Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
    Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, Mohamad Nasir Shafiee · 2023 · International Journal of Molecular Sciences
37. A pipeline for the development and analysis of extracellular vesicle-based transcriptomic biomarkers in molecular diagnostics
    Christian Grätz, Martina Schuster, Florian Brandes, Agnes Sophia Meidert, Benedikt Kirchner, Marlene Reithmair, Gustav Schelling, Michael Walter Pfaffl · 2024 · Molecular Aspects of Medicine
38. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma
    Nobuo Shinohara, Takashige Abe · 2015 · International Journal of Urology
39. Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
    Seri Jeong, Nuri Lee, Min-Jeong Park, Kibum Jeon, Wonkeun Song · 2021 · Cancers
40. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
    Jose Ignacio Lopez, Rafael Pulido, Jesús M. Cortés, J.C. Angulo, Charles Henderson Lawrie · 2018 · Pathology - Research and Practice
41. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases
    Jonathan J. Davick, Henry F. Frierson, Mark E. Smolkin, Alejandro Ariel Gru · 2018 · Human Pathology
42. Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling
    Theinmozhi Arulraj, Debashis Barik · 2018 · PLoS ONE
43. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
    Swati Gupta, Leena McCann, Yvonne G. Y. Chan, Edwin W. Lai, Wei Wei, Pok Fai Wong, James William Smithy, Jodi Marie Weidler, Brian K. Rhees, Michael Patrick Bates et al. · 2019 · Journal for ImmunoTherapy of Cancer
44. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas
    Federica Zito Marino, Giulio Rossi, Marco Montella, Gerardo Botti, Rossella De Cecio, Alessandro Morabito, Carmine La Manna, Andrea Ronchi, Mariacarolina Micheli, Giuseppe Salatiello et al. · 2019 · The American Journal of Surgical Pathology
45. Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy
    Jennifer Crow, Glenson Samuel, Andrew K. Godwin · 2019 · Expert Review of Molecular Diagnostics
46. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
    Jianguo Qiu, Wei Tang, Chengyou Du · 2020 · Current Cancer Drug Targets
47. Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer
    Huaiyu Zhang, Jiayu Zhang, Yilun Liu, Yang Jiang, Zhongmin Li · 2021 · Frontiers in Pharmacology
48. Optical cytosensors for the detection of circulating tumour cells
    Fereshteh Vajhadin, Mohammad Mazloum‐Ardakani, Alireza Sanati, Reihaneh Haghniaz, Jadranka Travaš‐Sejdić · 2022 · Journal of Materials Chemistry B
49. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer
    Benjamin Maurice Solomon, Ana Callejo, Jair Bar, Guy Berchem, Lyudmila A. Bazhenova, Pierre Saintigny, Fanny Wunder, Jacques Raynaud, Nicolas Girard, J. Jack Lee et al. · 2022 · Cancer Medicine
50. B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma
    Claudia Minici, Sabrina Gloria Giulia Testoni, Emanuel Della‐Torre · 2022 · Frontiers in Immunology
51. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
    Chunyan Xue, Dawei Zhu, Lujun Chen, Yun Xu, Bin Xu, Dachuan Zhang, Jingting Jiang · 2019 · Translational Cancer Research
52. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer
    Jiayue Yang, Zhen Tian, Han Gao, Fan Xiong, Cuiping Cao, Jiaojiao Yu, Wei Shi, Qiang Zhan, Cheng Yang · 2022 · BMC Cancer
53. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
    Matthieu Roulleaux Dugage, Víctor Albarrán-Artahona, Juan Carlos Laguna, Nathalie Chaput, Stéphane Vignot, Benjamin Besse, Laura Mezquita, Édouard Auclin · 2023 · European Journal of Cancer
54. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
    MinDong Sung, Won Seok Jang, Hae Reong Kim, Ji Ae Park, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Yu Rang Park, Min Hee Hong · 2023 · Translational Lung Cancer Research
55. Immune checkpoint inhibitors in sarcomas: a systematic review
    Μaria Anastasiou, Anastasios I. Kyriazoglou, Ioannis Kotsantis, Panagiota Economopoulou, Maria Kyrkasiadou, Anastasia E. Giannopoulou, Anastasia Kosmidou, D. Smerdi, Myrto K. Moutafi, Niki Gavrielatou et al. · 2023 · Immuno-Oncology Technology
56. Targeted therapy for advanced gastric cancer: A review of current status and future prospects
    Özkan Kanat, Bert H. O’Neil, Safi Shahda · 2015 · World Journal of Gastrointestinal Oncology
57. SARI , a novel target gene of glucocorticoid receptor, plays an important role in dexamethasone-mediated killing of B lymphoma cells
    Yinghui Huang, Jie Zhou, Yan Hong Huang, Jintao He, Yuting Wang, Chao‐Hui Yang, Dongbo Liu, Li Zhang, Fengtian He · 2016 · Cancer Letters
58. Translational biomarkers: from discovery and development to clinical practice
    Meena Subramanyam, Jaya Goyal · 2016 · Drug Discovery Today Technologies
59. Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract
    Kiichiro Teruya, Yoshihiro Kusumoto, Hiroshi Eto, Noboru Nakamichi, Sanetaka Shirahata · 2019 · Marine Drugs
60. Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer
    Hao Jiang, Rongjun Zhang, Huijie Jiang, Mingyu Zhang, Wei Guo, Jifeng Zhang, Xinglu Zhou, Wenbin Pan, Sheng Zhao, Ping Li · 2020 · Journal of Cancer
61. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study
    Kazuki Takada, Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Fumihiko Kinoshita, Yuki Ono, Sho Wakasu, Kensuke Tanaka, Yuka Oku et al. · 2020 · PLoS ONE
62. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control
    Steffen Markus Heckl, Franziska Mau, Anke Senftleben, Tina Daunke, Silje Beckinger, Samir Abdullazade, Stefan Schreiber, Christoph Röcken, Susanne Sebens, H. Schäfer · 2021 · Medical Sciences
63. Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine
    Hong, Xinqiang, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China, Dong, Tiangeng, Yi, Tuo, Hu, Jianwei, Zhang, Zhen, Lin, Shengli, Niu, Weixin · 2018 · Chinese Journal of Cancer Research
64. Immune Checkpoint Inhibitors for Brain Metastases
    Aaron C. Tan, Amy B. Heimberger, Alexander Maxwell Menzies, Nick Pavlakis, Mustafa Khasraw · 2017 · Current Oncology Reports
65. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications
    Jing He, Lei Huo, Junsheng Ma, Jun Zhao, Roland L. Bassett, Xiaoping Sun, Naoto Tada Ueno, Bora Lim, Yun Gong · 2017 · American Journal of Clinical Pathology
66. Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
    Witold Zgodziński, Ewelina Grywalska, Krzysztof Zinkiewicz, Agata Surdacka, Marek Majewski, Artur Zakościelny, Paweł Bury, Jacek Roliński, Grzegorz T. Wallner · 2018 · Archives of Medical Science
67. High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
    Min Hee Hong, Su‐Jin Shin, Sung Kwan Shin, Dae Joon Kim, Jae Ill Zo, Young Mog Shim, Seung Eun Lee, Byoung Chul Cho, Sung Yong Park, Yoon‐La Choi et al. · 2019 · Scientific Reports
68. Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
    Ishita Gupta, Balsam R. Rizeq, Semir Vranić, Ala‐Eddin Al Moustafa, Halema F. Al Farsi · 2020 · International Journal of Molecular Sciences
69. Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis
    Junya Yan, Xiaowen Wu, Jiayi Yu, Yanyan Zhu, Shundong Cang · 2020 · Frontiers in Oncology
70. Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode
    Paweł Niedziałkowski, Magdalena Bojko, Jacek Ryl, Anna Wcisło, Marta Spodzieja, Katarzyna Magiera‐Mularz, Katarzyna Guzik, Grzegorz Dubin, Tad A. Holak, Tadeusz Ossowski et al. · 2021 · Bioelectrochemistry
71. Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
    Shirin Karimi, Sheila Mansouri, Farshad Nassiri, Severa Bunda, Olivia Singh, Priscilla Kaliopi Brastianos, Ian F. Dunn, Gelareh Mohammed Zadeh · 2021 · Journal of Neuro-Oncology
72. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
    Qian Liu, Rongfang Nie, Mengyuan Li, Lin Li, Haiying Zhou, Hui Juan Lu, Xiaosheng Wang · 2021 · Computational and Structural Biotechnology Journal
73. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
    Wenxiang Zhang, Xiangyi Kong, Bolun Ai, Zhongzhao Wang, Xiangyu Wang, Nianchang Wang, Shan Zheng, Yi Fang, Jing Wang · 2021 · Frontiers in Oncology
74. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
    Davide Ciardiello, Brigida Anna Maiorano, Paola Parente, Maria Grazia Rodriquenz, Tiziana Pia Latiano, Cinzia Chiarazzo, Valerio Pazienza, Luigi Pio Guerrera, Brunella Amoruso, Nicola Normanno et al. · 2022 · International Journal of Molecular Sciences
75. Bias and inconsistency in the estimation of tumour mutation burden
    Mohammad A. Makrooni, Brian O’Sullivan, Cathal Seoighe · 2022 · BMC Cancer
76. Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer
    Green Hong, Pureum Sun, Chaeuk Chung, Dongil Park, Song‐I Lee, Nayoung Kim, Seong Eun Lee, Jeong Eun Lee, Yea Eun Kang, Da Hyun Kang · 2022 · Journal of Cancer Research and Clinical Oncology
77. Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
    Elizaveta Ivanova, Асадуллина Дилара Динаровна, Gulshat R. Gilyazova, Рахимов Радмир Радимович, Адель Альбертович Измайлов, В. Н. Павлов, Э. К. Хуснутдинова, I. R. Gilyazova · 2023 · Biomedicines
78. Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Akihiro Sakai, Hiroaki Iijima, Koji Ebisumoto, Mayu Yamauchi, Takanobu Teramura, Aritomo Yamazaki, Takane Watanabe, Toshihide Inagi, Daisuke Maki, Kenji Okami · 2023 · Cancers
79. Complementary roles of EP2 and EP4 receptors in malignant glioma
    Jian-Ge Qiu, Qianqian Li, Junqi Li, Feng-Mei Zhou, Peng Sang, Zhongkun Xia, Wei Wang, Lin Wang, Ying Yu, Jianxiong Jiang · 2023 · British Journal of Pharmacology
80. Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
    Ting Cao, Xuyang Zhou, Xingbiao Wu, Ying Zou · 2023 · Frontiers in Immunology
81. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
    Hirotaka Miyashita, Razelle Kurzrock, Nicholas Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Jeffrey M. Conroy, Paul DePietro et al. · 2023 · npj Genomic Medicine
82. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis
    Yin He, Xiaosheng Wang · 2023 · Computers in Biology and Medicine
83. Cell-cell communication network-based interpretable machine learning predicts cancer patient response to immune checkpoint inhibitors
    Juhun Lee, Donghyo Kim, JungHo Kong, Doyeon Ha, Inhae Kim, Minhyuk Park, Kwanghwan Lee, Sin‐Hyeog Im, Sanguk Kim · 2024 · Science Advances
84. Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation
    Enes Üçgül, Deniz Can Güven, Aybala Nur Ucgul, Yakup Özbay, Mehmet Ruhi Onur, Serkan Akın · 2024 · Cancer Control
85. Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases
    Ying Yu, Ka Yu Tse, Horace H.Y. Lee, Kin-Long Chow, Hing-Wai Tsang, Richard Wing-Cheuk Wong, Elaine Tin-Yan Cheung, Wah Cheuk, Victor Wai Kwan Lee, Wai‐Kong Chan et al. · 2019 · Modern Pathology
86. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma
    Maher A. Sughayer, Tamara Z. Dabbagh, Abdelkader Battah · 2020 · Applied immunohistochemistry & molecular morphology
87. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials
    Carmen Criscitiello, Antonio Marra, Stefania Morganti, Paola Zagami, Giulia Viale, Angela Espósito, Giuseppe Curigliano · 2020 · The Oncologist
88. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer
    Myeong Geun Choi, Yeon Joo Kim, Jae Cheol Lee, Jin Kyung Rho, Chang‐Min Choi · 2020 · Thoracic Cancer
89. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
    Ruiyu Li, Yangzhige He, Hui Zhang, Jing Wang, Xiaoding Liu, Hangqi Liu, Huanwen Wu, Zhiyong Liang · 2021 · Frontiers in Immunology
90. Setting Research Priorities for Kidney Cancer
    Jennifer Michelle Jones, Jaimin R. Bhatt, Jonathan Avery, Andreas Laupacis, Katherine Cowan, Naveen S. Basappa, Joan Basiuk, Christina Canil, Sohaib Al-Asaaed, Daniel Y.C. Heng et al. · 2017 · European Urology
91. Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer
    Yaobang Wang, Wuyue Song, Chao Feng, Shulin Wu, Zezu Qin, Tao Liu, Yu Ye, Rong Huang, Yuanliang Xie, Zhonghua Tang et al. · 2024 · Journal of Translational Medicine
92. PD-L1 expression in prostate cancer and Gleason Grade Group: Is there any relationship? Findings from a multi-institutional cohort.
    Vincenzo Fiorentino, Ludovica Rita Pepe, Cristina Pizzimenti, Valeria Zuccalà, Pietro Pepe, Vincenzo Cianci, Cristina Mondello, Giovanni Tuccari, Guido Fadda, Giuseppe Giuffrè et al. · 2025 · Pathology - Research and Practice
93. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma
    Yosuke Kubo, Satoshi Fukushima, Yukiko Inamori, Mina Tsuruta, Sho Egashira, Saori Yamada‐Kanazawa, Satoshi Nakahara, Aki Tokuzumi, Azusa Miyashita, Jun Aoi et al. · 2018 · Journal of Dermatological Science
94. Gated Resonance Energy Transfer (gRET) Controlled by Programmed Death Protein Ligand 1
    Hubert Grel, Katarzyna Ratajczak, Sławomir Jakieła, Magdalena Stobiecka · 2020 · Nanomaterials
95. m6A RNA Methylation Regulators Impact Prognosis and Tumor Microenvironment in Renal Papillary Cell Carcinoma
    Lianze Chen, Baohui Hu, Xinyue Song, Lin Wang, Mingyi Ju, Zinan Li, Chenyi Zhou, Ming Zhang, Qian Wei, Qiutong Guan et al. · 2021 · Frontiers in Oncology
96. PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis
    Miaomiao Gou, Yong Zhang, Tiee Liu, Haiyan Si, Zhikuan Wang, Huan Yan, Niansong Qian, Guanghai Dai · 2021 · Frontiers in Oncology
97. Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues
    Hazem Ghebeh, Fatmah A. Mansour, Dilek Çolak, Akram A. Alfuraydi, Amal A. Al-Thubiti, Dorota Monies, Monther M Al-Alwan, Taher Al‐Tweigeri, Asma M. Tulbah · 2021 · Antibodies
98. The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells
    Xiaotian Yan, Jie Feng, Bo Hong, Yun Qian · 2021 · Frontiers in Oncology
99. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma
    Mary Wong, Jong T Kim, Brian K. Cox, Brent K. Larson, Stacey Kim, Kevin M. Waters, Eric Vail, Maha M. Guindi · 2021 · Hepatic Oncology
100. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab
     Kousuke Ueda, Shigetaka Suekane, Hirofumi Kurose, Naoyuki Ogasawara, Tasuku Hiroshige, Katsuaki Chikui, Keiichiro Uemura, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo et al. · 2021 · Japanese Journal of Clinical Oncology